Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Current Deferred Revenue: 2009-2014

Historic Current Deferred Revenue for Vanda Pharmaceuticals (VNDA) over the last 6 years, with Dec 2014 value amounting to $247,000.

  • Vanda Pharmaceuticals' Current Deferred Revenue fell 99.73% to $247,000 in Q4 2014 from the same period last year, while for Dec 2014 it was $247,000, marking a year-over-year decrease of 99.73%. This contributed to the annual value of $247,000 for FY2014, which is 99.73% down from last year.
  • As of FY2014, Vanda Pharmaceuticals' Current Deferred Revenue stood at $247,000, which was down 99.73% from $90.3 million recorded in FY2013.
  • Vanda Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $170.6 million during FY2010, with a 5-year trough of $247,000 in FY2014.
  • Over the past 3 years, Vanda Pharmaceuticals' median Current Deferred Revenue value was $90.3 million (recorded in 2013), while the average stood at $69.2 million.
  • Data for Vanda Pharmaceuticals' Current Deferred Revenue shows a maximum YoY crashed of 99.73% (in 2014) over the last 5 years.
  • Over the past 5 years, Vanda Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $170.6 million in 2010, then fell by 15.70% to $143.9 million in 2011, then decreased by 18.62% to $117.1 million in 2012, then dropped by 22.88% to $90.3 million in 2013, then crashed by 99.73% to $247,000 in 2014.